COMBINATION OF THERAPEUTIC DRUG MONITORING AND GENOTYPING IN PHARMACOTHERAPY

Year 2023, Volume: 27 Issue: Current Research Topıcs In Pharmacy: Therapeutic Drug Monitoring, 7 - 8, 28.06.2025

Halit Sinan Süzen

Abstract

Development of adverse drug reactions (ADRs) and inefficient or excessive respond to medications are still important problems during pharmacotherapy. Therapeutic Drug Monitoring (TDM) is one of the valuable tools to overcome medication related issues in either clinical or outpatients [1]. TDM is quantification of the medications and their pharmacologically active metabolites in biological tissues, mostly blood plasma or serum. The stages of TDM consists of several compartments including chemical analysis, pharmacokinetics and pharmacodynamics. There is no need to perform TDM for all medications. The established necessities for conducting TDM are narrow therapeutic index/range of medication, therapeutic failure, medication toxicity, unpredictable relationship between dose and clinical outcome, large variation in metabolism of medications, and detect drug abuse. Since TDM assay results have a great impact on medication treatment, accuracy of TDM report is vital. On the other hand, it should be considered that some factors may have change blood medication levels. These are age, gender, body weight, diseases, pregnancy, lactation medication interactions, pharmacogenetics and blood sampling time. Various analytical methods have been used for TDM service and investigations. These are mainly chromatographic (GC-MS, HPLC, LC-MS) and immuno binding assays methods (Fluorescence Polarization Immuno Assay-FPIA, Enzyme Immunoassay-EMIT, enzyme-linked Immunosorbent assay and Chemiliumericense). Although immunoassays are more economic and fast than chromatographic methods, their sensitivity, specificity, and accuracy concerning the target medication is lower than chromatographic techniques. Enormous technical developments in molecular biology methods and understanding of our genome function have been given prominent contribution to medication treatment especially in last two decades. Number of actionable pharmacogenetics biomarkers has been increasing for considerable number of medications [2]. Thus, combination of genotyping for particular medications together with TDM has a great potential to achieve successful treatment with minimising adverse drug reactions in pharmacotherapy.

Keywords

Therapeutic Drug Monitoring (TDM) , genotyping , pharmacotherapy

References

• [1] Gross AS. Best practice in therapeutic drug monitoring. Br J Clin Pharmacol. 1998 46(2):95-99. [CrossRef]
• [2] Yamazaki S. A retrospective analysis of actionable pharmacogenetic/genomic biomarker language in FDA labels. Clin Transl Sci. 2021 1(4):1412-1422. [CrossRef]